Evidence map›Paper›PMID 30542695›Full record

ArticleOncology reports2019

Bromodomain PHD‑finger transcription factor promotes glioma progression and indicates poor prognosis.

Yanling Pan, Feng Yuan, Yijie Li, Guoping Wang, Zhiren Lin, Longhua Chen

Open access · hybridAbstract read
In one paragraph

Article in Oncology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Lumbrokinase Extracted fromBiomolecules · 2024
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. miR-454-3p promotes of human glioma cell growth by targeting EGR3.Experimental and therapeutic medicine · 2019
    Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Yanling PanDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China.
Feng YuanDepartment of Radiation Oncology, Haikou People's Hospital, Haikou, Hainan 570208, P.R. China.
Yijie LiDepartment of Radiation Oncology, Haikou People's Hospital, Haikou, Hainan 570208, P.R. China.
Guoping WangDepartment of Radiation Oncology, Haikou People's Hospital, Haikou, Hainan 570208, P.R. China.
Zhiren LinDepartment of Radiation Oncology, Haikou People's Hospital, Haikou, Hainan 570208, P.R. China.
Longhua ChenDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China.
Haikou City People's Hospital · CNNanfang Hospital · CNSouthern Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioma is one of the most deadly central nervous system tumors around the world. Uncontrollable cell proliferation and invasion are key factors of cancer progression as well as glioma. Available evidence suggests that bromodomain PHD‑finger transcription factor (BPTF) plays an important role in stem cell proliferation and differentiation, as well as in progression of some tumors, but there is little data on glioma. Therefore, the present study aimed to explore the functional role and potential clinical value of BPTF in glioma. Public database, real‑time PCR and western blotting were used to detect the expression of BPTF in glioma tissue and cells. The relationship between BPTF with clinicopathological features and the prognosis of glioma patients was analyzed by immunohistochemical staining in 113 cases of paraffin‑embedded primary glioma specimens. Furthermore, cytological experiments were conducted to elucidate the functional role of BPTF in glioma U251 cells, as well as the potential molecular mechanism. The expression of BPTF in glioma tissues was significantly higher than that in normal brain tissues. The association analysis results revealed that high BPTF expression was significantly associated with WHO grade and tumor size. Survival analysis revealed that the BPTF high‑expression group had poorer overall survival (OS) and progression‑free survival (PFS) compared with the low‑expression group. Univariate and multivariate Cox regression analyses revealed that BPTF expression was an independent prognostic factor for the OS and PFS of glioma patients. Cytological experiments revealed that BPTF overexpression could significantly promote the proliferation, migration and invasion of human glioma U251 cells. A study of the underlying mechanism indicated that BPTF promoted glioma progression via MYC signaling. Our results preliminarily indicated that BPTF promoted glioma progression via MYC signaling and may be a potential prognostic biomarker and therapeutic target for glioma patients.

Indexed as

AdultAgedAged, 80 and overAntigens, NuclearBiomarkers, TumorBrain NeoplasmsBromodomain Containing ProteinsDisease ProgressionFemaleGliomaHumansMaleMiddle AgedNeoplasm GradingNerve Tissue ProteinsPrognosisAntigens, NuclearBiomarkers, TumorBromodomain Containing Proteinsfetal Alzheimer antigenMYC protein, humanNerve Tissue ProteinsProto-Oncogene Proteins c-mycTranscription Factors

Identifiers

PMID30542695
PMCPMC6278589
OpenAlexW2898850434

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.